Patents by Inventor Anna SLAGER

Anna SLAGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccines For Recurrent Respiratory Papillomatosis And Methods Of Using The Same
    Publication number: 20260053908
    Abstract: Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.
    Type: Application
    Filed: October 29, 2025
    Publication date: February 26, 2026
    Inventors: Stephanie Ramos, Jewell Walters, Jian Yan, Anna Slager, Charles Reed, Kate Broderick
  • Vaccines for recurrent respiratory papillomatosis and methods of using the same
    Patent number: 12478667
    Abstract: Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.
    Type: Grant
    Filed: July 17, 2023
    Date of Patent: November 25, 2025
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Stephanie Ramos, Jewell Walters, Jian Yan, Anna Slager, Charles Reed, Kate Broderick
  • CANCER VACCINES TARGETING MUC16 AND USES THEREOF
    Publication number: 20250222086
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus MUC161 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen are disclosed. Methods of treating a subject with a MUC16-expressing tumor and methods of preventing a MUC16-expressing tumor are disclosed. Modified consensus MUC16 antigen is disclosed.
    Type: Application
    Filed: March 25, 2025
    Publication date: July 10, 2025
    Inventors: Jian YAN, Anna SLAGER, Bradley GARMAN, Neil COOCH
  • Cancer vaccines targeting MUC16 and uses thereof
    Patent number: 12285473
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen are disclosed. Methods of treating a subject with a MUC16-expressing tumor and methods of preventing a MUC16-expressing tumor are disclosed. Modified consensus MUC16 antigen is disclosed.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: April 29, 2025
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • CANCER VACCINES TARGETING BORIS AND USES THEREOF
    Publication number: 20250057929
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen are disclosed. Methods of treating a subject with a BORIS-expressing tumor and methods of preventing a BORIS-expressing tumor are disclosed. A synthetic consensus BORIS antigen is disclosed.
    Type: Application
    Filed: November 1, 2024
    Publication date: February 20, 2025
    Inventors: Jian YAN, Anna SLAGER, Bradley GARMAN, Neil COOCH
  • Cancer vaccines targeting BORIS and uses thereof
    Patent number: 12161706
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen are disclosed. Methods of treating a subject with a BORIS-expressing tumor and methods of preventing a BORIS-expressing tumor are disclosed. A synthetic consensus BORIS antigen is disclosed.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: December 10, 2024
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • CANCER VACCINES TARGETING SURVIVIN AND USES THEREOF
    Publication number: 20240358809
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens are disclosed. Methods of treating a subject with a Survivin-expressing tumor and methods of preventing a Survivin-expressing tumor are disclosed. Synthetic consensus Survivin antigens are disclosed.
    Type: Application
    Filed: July 8, 2024
    Publication date: October 31, 2024
    Inventors: Jian YAN, Anna SLAGER, Bradley GARMAN, Neil COOCH
  • CANCER VACCINES TARGETING MESOTHELIN AND USES THEREOF
    Publication number: 20240285741
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen are disclosed. Methods of treating a subject with a mesothelin-expressing tumor and methods of preventing a mesothelin-expressing tumor are disclosed. Modified consensus mesothelin antigen is disclosed.
    Type: Application
    Filed: April 16, 2024
    Publication date: August 29, 2024
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • Cancer vaccines targeting Survivin and uses thereof
    Patent number: 12064473
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode synthetic consensus Survivin antigens are disclosed. Methods of treating a subject with a Survivin-expressing tumor and methods of preventing a Survivin-expressing tumor are disclosed. Synthetic consensus Survivin antigens are disclosed.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: August 20, 2024
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • Cancer vaccines targeting mesothelin and uses thereof
    Patent number: 11986517
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus mesothelin antigen are disclosed. Methods of treating a subject with a mesothelin-expressing tumor and methods of preventing a mesothelin-expressing tumor are disclosed. Modified consensus mesothelin antigen is disclosed.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: May 21, 2024
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • Vaccines For Recurrent Respiratory Papillomatosis And Methods of Using the Same
    Publication number: 20240123052
    Abstract: Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.
    Type: Application
    Filed: October 13, 2023
    Publication date: April 18, 2024
    Inventors: Stephanie Ramos, Jewell Walters, Jian Yan, Anna Slager, Charles Reed, Kate Broderick
  • Vaccines For Recurrent Respiratory Papillomatosis And Methods Of Using The Same
    Publication number: 20230414744
    Abstract: Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.
    Type: Application
    Filed: July 17, 2023
    Publication date: December 28, 2023
    Inventors: Stephanie Ramos, Jewell Walters, Jian Yan, Anna Slager, Charles Reed, Kate Broderick
  • Vaccines for recurrent respiratory papillomatosis and methods of using the same
    Patent number: 11744885
    Abstract: Provided herein are nucleic acid molecules encoding an HPV antigen. Also provided are vaccines against human papillomavirus (HPV) comprising the nucleic acids, methods of inducing immune responses, and methods for prophylactically and/or therapeutically immunizing individuals against recurrent respiratory papillomatosis (RRP). Pharmaceutical compositions, recombinant vaccines comprising DNA plasmid and live attenuated vaccines are disclosed as well as methods of inducing an immune response to treat or prevent RRP are disclosed.
    Type: Grant
    Filed: May 14, 2021
    Date of Patent: September 5, 2023
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Stephanie Ramos, Jewell Walters, Jian Yan, Anna Slager, Charles Reed, Kate Broderick
  • CANCER VACCINES TARGETING LEMD1 AND USES THEREOF
    Publication number: 20220265800
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen are disclosed. Methods of treating a subject with a LEMD1-expressing tumor and methods of preventing a LEMD1-expressing tumor are disclosed. Mutated consensus LEMD1 antigen is disclosed.
    Type: Application
    Filed: April 25, 2022
    Publication date: August 25, 2022
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • Cancer Vaccines Targeting PRAME and Uses Thereof
    Publication number: 20220265801
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen are disclosed. Methods of treating a subject with a PRAME-expressing tumor and methods of preventing a PRAME-expressing tumor are disclosed. Mutated consensus PRAME antigen is disclosed.
    Type: Application
    Filed: April 25, 2022
    Publication date: August 25, 2022
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • Cancer vaccines targeting PRAME and uses thereof
    Patent number: 11338029
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus PRAME antigen are disclosed. Methods of treating a subject with a PRAME-expressing tumor and methods of preventing a PRAME-expressing tumor are disclosed. Mutated consensus PRAME antigen is disclosed.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 24, 2022
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • Cancer vaccines targeting LEMD1 and uses thereof
    Patent number: 11338028
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a mutated consensus LEMD1 antigen are disclosed. Methods of treating a subject with a LEMD1-expressing tumor and methods of preventing a LEMD1-expressing tumor are disclosed. Mutated consensus LEMD1 antigen is disclosed.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: May 24, 2022
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • CANCER VACCINES TARGETING MUC16 AND USES THEREOF
    Publication number: 20220111026
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen are disclosed. Methods of treating a subject with a MUC16-expressing tumor and methods of preventing a MUC16-expressing tumor are disclosed. Modified consensus MUC16 antigen is disclosed.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Inventors: Jian YAN, Anna SLAGER, Bradley GARMAN, Neil COOCH
  • Cancer vaccines targeting MUC16 and uses thereof
    Patent number: 11235044
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen are disclosed. Methods of treating a subject with a MUC16-expressing tumor and methods of preventing a MUC16-expressing tumor are disclosed. Modified consensus MUC16 antigen is disclosed.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: February 1, 2022
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventors: Jian Yan, Anna Slager, Bradley Garman, Neil Cooch
  • CANCER VACCINES TARGETING BORIS AND USES THEREOF
    Publication number: 20210401958
    Abstract: Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a synthetic consensus BORIS antigen are disclosed. Methods of treating a subject with a BORIS-expressing tumor and methods of preventing a BORIS-expressing tumor are disclosed. A synthetic consensus BORIS antigen is disclosed.
    Type: Application
    Filed: September 20, 2021
    Publication date: December 30, 2021
    Inventors: Jian YAN, Anna SLAGER, Bradley GARMAN, Neil COOCH